医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Rexahn Pharmaceuticals Awarded Patent in Japan for Novel Anti-cancer Isoquinolinamine Compounds  

2013年07月09日 PM09:25
このエントリーをはてなブックマークに追加


 

ROCKVILLE, Md.

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing potential best-in-class oncology therapies, today announced that the Japan Patent Office has granted Patent No. 5270564 covering a series of novel isoquinolinamine compounds, their pharmaceutical composition, and method for producing an anti-tumor effect.

The patent includes inhibitors of the kinase activity of Aurora A, a family of mitotic serine/threonine kinases. Aurora A kinase has been shown to be over-expressed in many human cancer tumors including breast, colon, leukemia, lung, head and neck, ovarian and prostate. In preclinical studies, Rexahn’s lead compound has shown anti-tumor activity against human cancer cell lines that do not respond well to paclitaxel, gemcitabine and cisplatin.

“The granting of this patent further strengthens Rexahn’s intellectual property position in this exciting area. The preclinical activity of the compound suggests its potential utility to treat multiple forms of cancer including breast, colon, leukemia, lung, head and neck, ovarian and prostate.” commented Peter D. Suzdak, CEO of Rexahn.

Rexahn has been awarded patents for the isoquinolinamine compounds in the United States, Europe, Australia, China, Mexico, and now Japan.

About Rexahn Pharmaceuticals, Inc.

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has three clinical stage oncology candidates, Archexin®, RX-3117, and RX-5902 and a robust pipeline of preclinical compounds to treat multiple types of cancer. Rexahn has also developed proprietary drug discovery platform technologies in the areas of nano-medicines, 3D-GOLD, and TIMES. For more information, please visit www.rexahn.com.

Safe Harbor

To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about Rexahn’s plans, objectives, expectations and intentions with respect to future operations and products and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause Rexahn’s actual results to be materially different than those expressed in or implied by Rexahn’s forward-looking statements. For Rexahn, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of Rexahn’s licensees or sublicensees; the success of clinical testing; and Rexahn’s need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect Rexahn’s actual results are described in Rexahn’s filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. Rexahn undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

CONTACT

The Trout Group LLC
Tricia Truehart, 646-378-2953
ttruehart@troutgroup.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent